A national workshop for respiratory leaders across primary, secondary, tertiary care and commissioning. It will focus on improvements in uncontrolled and severe asthma pathways and share learning from the two-year asthma biologics programme led by the Oxford AHSN on behalf of the AHSN Network in partnership with the NHS Accelerated Access Collaborative (AAC).
Up to 200,000 people in the UK have uncontrolled or severe asthma, which has a huge impact on the lives of patients and their families. Many are frequently admitted to hospital as an emergency and can experience life-threatening asthma attacks.
Asthma biologics work in a targeted way by disrupting pathways causing airways inflammation, helping to manage symptoms and reduce relapses for those with severe asthma. These therapies can transform patients’ lives by reducing long-term side effects of other treatments, such as steroids, and reduce the number of life-threatening asthma attacks.
From April 2021 to March 2023 AHSNs in England supported the adoption and spread of asthma biologics, under the AAC Rapid Uptake Products programme. More than 4,690 new patients have been initiated onto asthma biologics and around 3,000 fewer patients were prescribed 3g or more of oral steroid prednisolone each month.
Hosted by the Oxford AHSN, this workshop will be chaired by Dr Hitasha Rupani, clinical champion for the asthma biologics programme and consultant respiratory physician at University Hospital Southampton NHS Foundation Trust.